LAVA Therapeutics N.V. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2021. For the quarter, the company reported research and license revenue of EUR 897,000 compared to EUR 592,000 a year ago. Operating loss was EUR 5,467,000 compared to EUR 3,154,000 a year ago. Net loss was EUR 5,784,000 compared to EUR 3,469,000 a year ago. Net loss per share, basic and diluted was EUR 0.23 compared to EUR 7.75 a year ago. For the six months, the company reported research and license revenue of EUR 1,818,000 compared to EUR 592,000 a year ago. Operating loss was EUR 21,700,000 compared to EUR 6,771,000 a year ago. Net loss was EUR 22,358,000 compared to EUR 7,147,000 a year ago. Net loss per share, basic and diluted was EUR 1.64 compared to EUR 15.97 a year ago.